“Excess adiposity should be confirmed by at least one other anthropometric criterion (eg, waist circumference) or by direct fat measurement when available. However, in people with substantially high BMI levels (ie, >40 kg/m2) excess adiposity can be pragmatically assumed
People with confirmed obesity (that is, with clinically documented excess adiposity) should then be assessed for possible clinical obesity based on findings from medical history, physical examination, and standard laboratory tests…”
(The GLP1 drugs are favorites for Dr Varipapa, improving health in so many ways!)
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current medications in alleviating symptoms.
(Dr Varipapa suspects Mounjaro and Zepbound to have similar if not better benefit as it is even better for treatment of obesity!)
The blockbuster drug semaglutide, sold as Ozempic for diabetes and as Wegovy for weight loss, now has a new proven benefit: It markedly soothed knee pain in people who are obese and have moderate to severe osteoarthritis, according to a large study.
The effect was so pronounced that some arthritis experts not involved with the clinical trial were taken aback.
“The magnitude of the improvement is of a scope we haven’t seen before with a drug,” said Dr. Bob Carter, deputy director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. “They had an almost 50 percent reduction in their knee pain. That’s huge.”
Want to reduce food cravings, lose weight and improve glucose control?
The GLP-1 Probiotic is formulated with beneficial bacterial strains that naturally increase GLP-1, the ‘un-hunger’ hormone that helps curb cravings and appetite. Presently at the time of this post, the Pendulum Probiotics are the only ones that have had double blind research with publications in peer-reviewed medical journals.
There is also a company webinar that is very informative:
You can also use your FSA or HSA account as payment too. Certainly worth a try if you are serious about your health. More information at the Pendulum Life website:
Delaware is 43rd among states in the US with 38% of the population considered obese! For comparison, West Virginia is 50th with 41% obese, and Colorado ranked 1st with 25% obese.
GLP-1 medications semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are expensive treatment options for obesity, usually $1,000 or more per month (although insurers and PBM’s pay less – I’ve heard around $500 +/-) The State of Delaware is currently blaming the expense of these medications on the increase in cost of the State Employee benefit programs.
Not factored in are the savings from complications of diabetes and hypertension and the reduction in cardiovascular and orthopedic disorders (savings which may take years to show up.)
Presently, Delaware has been spending about $2.5 million a month on these drugs – total health plan spending over the first six months is about $15 million, which would equate to $30 million per year!
Delaware chose to cover the drugs last March and is now reassessing whether to make changes to its coverage policies. The State Employee Benefits Committee, which oversees Delaware’s health care plans for state workers and retirees, will be discussing this issue at upcoming meetings on Feb. 20, March 11 and 25 before making a recommendation to the State. Email the benefits committee at sebc@delaware.gov if you would like to comment.
According to a recent NPR story on Delaware Public Media, drugs like Ozempic can help weight loss, but not without ethical and health concerns.
“North Carolina shouldered the cost of the weight loss drug Wegovy for 2,800 state workers in 2021. Last year, that number shot up to 25,000 totaling $100 million.
Last Thursday, the state decided not to pay for it any longer. Celebrities and people like Elon Musk who can afford $1,000 a month for Ozempic and Wegovy can still get them. However, a nurse in North Carolina told The New York Times that finding Wegovy is like winning the lottery.
These Food and Drug Administration-approved, plant-based injectable drugs were initially developed to treat diabetes, but they also help with obesity. But demand for Ozempic and Wegovy’s weight-loss properties rose so high that diabetics had trouble finding them. There aren’t enough chemicals to keep up with the demand, creating a scarcity.”
CNMRI: Neurology, Sleep Medicine, MRI 